NCT05067387

Evaluation of Oral THC and CBD in Men and Women

Evaluation of Oral THC and CBD in Oral Fluid, Pharmacokinetics, and Subjective and Neurocognitive Effects in Men and Women

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 22 (estimated)
• Sponsor: University of California, Los Angeles · Academic / Other
• Sex: All
• Age: 21 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.

Detailed description

This double-blind placebo controlled, within-subject study study will assess testing devices that can measure biochemical markers in oral fluid and neurocognitive-performance markers of recent THC or CBD use. Other pharmacodynamic effects of oral THC or CBD will be determined and the pharmacokinetics of THC, CBD, and respective metabolites will be assessed in whole blood.

Conditions

• Drug Abuse
• Intoxication by Drug
• Impairment

Interventions

Type	Name	Description
DRUG	Placebo	Oral placebo
DRUG	THC	Oral THC (20 mg)
DRUG	CBD	Oral CBD (20 mg)
DRUG	THC + CBD	Oral THC (20 mg) + CBD (20 mg)

Timeline

• Start date: 2026-04-15
• Primary completion: 2027-06-15
• Completion: 2028-06-15
• First posted: 2021-10-05
• Last updated: 2026-02-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study